How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...
The layoffs were part of wider cuts at Microsoft, as the company prioritizes spending on artificial intelligence. By Karen Weise and Zachary Small Other outstanding efforts reimagine the American ...
A critical readout on Wednesday of the first Federal Reserve policy meeting overseen by Chairman Kevin Warsh may offer greater insight into the "family fight" the new central bank leader said ...
Some people want to use a small screen, and some people like to use a multiple monitor setup to do every single task including viewing videos. If you have multiple monitors for everyday use, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results